With a $83.5 billion market value, Celgene Corp (NASDAQ:CELG) ranks in the top 10% of its industry group, Biotechnology, and in the top decile of sector group, Health Care, in market value. From the prospective of investment attractiveness, The current Portfolio Grader ranking for CELG puts it 183 among the 350 companies in this industry group, giving it a below-average spot; in the third quartile of the sector with a ranking of 419 among the 782 companies in the sector, and number 2,574 in the nearly 5,000 company Portfolio Grader universe.

With a $80.4 billion market value, Celgene Corp (NASDAQ:CELG) ranks in the top decile in its industry group, Biotechnology, and in the top decile of sector group, Health Care, in market value. From the vantage point of investment attractiveness, The current Portfolio Grader ranking for CELG puts it 218 among the 350 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 499 among the 782 companies in the sector, and number 3,010 in the nearly 5,000 company Portfolio Grader universe.

Celgene Corp (NASDAQ:CELG) is a constituent of the 349 company Biotechnology GICS industry group, which is a segment of the 781 company GICS Health Care sector. CELG has a market value of $82.3 billion which is in the top decile in its industry group. The current Portfolio Grader ranking for CELG puts it 198 among the 349 companies in this industry group, giving it a below-average spot; in the third quartile of the sector with a ranking of 477 among the 781 companies in the sector, and number 3,032 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Sell for Celgene Corp (NASDAQ:CELG) has been derived by using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month.

The current recommendation of Sell for Celgene Corp (NASDAQ:CELG) is derived using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. CELG has maintained this ranking for the last month.

Portfolio Grader currently ranks Celgene Corp (NASDAQ:CELG) a Sell. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

Celgene Corp (NASDAQ:CELG) is ranked as a Sell using Louis Navellier's investing system and his Portfolio Grader stock evaluator. The shares have been downgraded from a Buy to a Sell in the last week.